UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): February 9, 2026 |
PLUS THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-34375 |
33-0827593 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
6420 LEVIT GREEN BOULEVARD Suite 310 |
|
Houston, Texas |
|
77021 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (737) 255-7194 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share |
|
PSTV |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 9, 2026, Plus Therapeutics, Inc. (the “Company”) filed a Registration Statement on Form S-1 (File No. 333-292637) with the Securities and Exchange Commission (as amended, the “Registration Statement”). Pursuant to Instruction 1 to Item 402(c)(2)(iii) and (iv) of Regulation S-K, the “Summary Compensation Table for 2025 and 2024” included in the Registration Statement noted that the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) had not yet determined the amount of discretionary cash bonuses payable to the Company’s principal executive officer and up to two of the most highly compensated executive officers other than the principal executive officer (the “Named Executive Officers”) for the fiscal year ended December 31, 2025 (“Fiscal Year 2025”), and that the amounts of such discretionary cash bonuses would be disclosed in a Current Report on Form 8-K under Item 5.02(f) once the amounts are determined.
On February 9, 2026, the Compensation Committee approved discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025. In accordance with Item 5.02(f) of Form 8-K, set forth below is an updated “Summary Compensation Table for 2025 and 2024”, which includes the amount of discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025, as well as the total compensation figures for the Company’s Named Executive Officers for Fiscal Year 2025.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NEO |
|
Year |
|
|
Salary
($) |
|
|
Option
Awards
($)(1) |
|
|
Restricted
Stock
Awards
($)(1) |
|
|
Non-Equity
Incentive Plan
Compensation
($) |
|
|
All Other
Compensation
($)(2) |
|
|
Total
($) |
|
Marc H. Hedrick, M.D. President and Chief Executive Officer |
|
|
2025 |
|
|
|
585,000 |
|
|
|
3,531,841 |
|
|
|
1,100,647 |
|
|
|
305,663 |
|
|
|
43,581 |
|
|
|
5,566,732 |
|
|
|
2024 |
|
|
|
556,400 |
|
|
|
335,348 |
|
|
|
— |
|
|
|
321,321 |
|
|
|
47,216 |
|
|
|
1,260,285 |
|
|
|
|
|
|
|
|
|
Andrew Sims Chief Financial Officer |
|
|
2025 |
|
|
|
390,000 |
|
|
|
810,388 |
|
|
|
264,154 |
|
|
|
149,175 |
|
|
|
17,562 |
|
|
|
1,631,279 |
|
|
|
2024 |
|
|
|
372,750 |
|
|
|
74,758 |
|
|
|
— |
|
|
|
156,555 |
|
|
|
17,053 |
|
|
|
621,116 |
|
|
|
|
|
|
|
|
|
Norman LaFrance, M.D.(3) Former Chief Medical Officer |
|
|
2025 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2024 |
|
|
|
258,446 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
27,466 |
|
|
|
285,912 |
|
(1)The amounts in this column reflect the aggregate grant date fair value of share-based awards granted to our NEOs during the years indicated. In accordance with SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions computed in accordance with ASC Topic 718.
(2)This column includes standard benefits, including a 401K match, and health and life insurance premiums.
(3)On June 11, 2024, Dr. LaFrance stepped down from his position as the Company’s Chief Medical Officer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
PLUS THERAPEUTICS, INC. |
|
|
|
|
Date: |
February 13, 2026 |
By: |
/s/ Marc H. Hedrick, M.D. |
|
|
|
Marc H. Hedrick, M.D.
President and Chief Executive Officer |